Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry)
- Authors
- Filippo, O.D.; Kang, Jeehoon; Bruno, F.; Han, Jung-Kyu; Saglietto, A.; Yang, Han-Mo; Patti, G.; Park, Kyung-Woo; Parma, R.; Kim, Hyo-Soo; Luca, L.D.; Gwon, Hyeon-Cheol; Iannaccone, M.; Chun, Woo Jung; Smolka, G.; Hur, Seung-Ho; Cerrato, E.; Han, Seung Hwan; Mario, C.D.; Song, Young Bin; Escaned, J.; Choi, Ki Hong; Helft, G.; Doh, Joon-Hyung; Giachet, A.T.; Hong, Soon-Jun; Muscoli, S.; Nam, Chang-Wook; Gallone, G.; Capodanno, D.; Trabattoni, D.; Imori, Y.; Dusi, V.; Cortese, B.; Montefusco, A.; Conrotto, F.; Colonnelli, I.; Sheiban, I.; Ferrari, G.M.D.; Koo, Bon-Kwon; D'Ascenzo, F.
- Issue Date
- 1-Oct-2021
- Publisher
- EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
- Citation
- American Journal of Cardiology, v.156, pp.16 - 23
- Journal Title
- American Journal of Cardiology
- Volume
- 156
- Start Page
- 16
- End Page
- 23
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82103
- DOI
- 10.1016/j.amjcard.2021.07.005
- ISSN
- 0002-9149
- Abstract
- Optimal dual antiplatelet therapy (DAPT) duration for patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcations is an unmet issue. The BIFURCAT registry was obtained by merging two registries on coronary bifurcations. Three groups were compared in a two-by-two fashion: short-term DAPT (≤ 6 months), intermediate-term DAPT (6-12 months) and extended DAPT (>12 months). Major adverse cardiac events (MACE) (a composite of all-cause death, myocardial infarction (MI), target-lesion revascularization and stent thrombosis) were the primary endpoint. Single components of MACE were the secondary endpoints. Events were appraised according to the clinical presentation: chronic coronary syndrome (CCS) versus acute coronary syndrome (ACS). 5537 patients (3231 ACS, 2306 CCS) were included. After a median follow-up of 2.1 years (IQR 0.9-2.2), extended DAPT was associated with a lower incidence of MACE compared with intermediate-term DAPT (2.8% versus 3.4%, adjusted HR 0.23 [0.1-0.54], p <0.001), driven by a reduction of all-cause death in the ACS cohort. In the CCS cohort, an extended DAPT strategy was not associated with a reduced risk of MACE. In conclusion, among real-world patients receiving PCI for coronary bifurcation, an extended DAPT strategy was associated with a reduction of MACE in ACS but not in CCS patients. © 2021 Elsevier Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82103)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.